Pegfilgrastim
| Pegfilgrastim | ||
|---|---|---|
| Mass / length primary structure | 175 amino acids + PEG, 39.0 kDa | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| ATC code | L03 AA13 | |
| DrugBank | BTD00094 | |
| Drug class | Growth factor | |
Pegfilgrastim is a recombinant , PEGylated human granulocyte colony stimulating factor (G-CSF) that stimulates the formation of leukocytes . As a result of PEGylation, pegfilgrastim has a longer half-life of 15 to 80 hours than the unPEGylated filgrastim (approx. 3.5 hours).
Clinical information
Pegfilgrastim is often used in chemotherapy- induced leukopenia and is injected subcutaneously .
When side effects (NW) bone pain, headache, flu-like symptoms and fever may occur (see a.. Northwest of G-CSF ).
right
In 2002 Roche ceded its rights to Filgrastim and Pegfilgrastim and the corresponding assets for the European Union , Switzerland and Norway to the US company Amgen for USD 137.5 million . This after Roche's Japanese subsidiary announced a merger with the Japanese Chugai Pharmaceutical Co. With Lenograstim, Chugai sells a competing product .
Roche's license rights in the regions of Eastern Europe, Middle East, Africa, Asia and Latin America are not affected .
Trade names
Neulasta (D, CH), Neupopeg (A)
Biosimilars : Pelgraz (D)
Web links
- Pharmaceutical newspaper online: pegfilgrastim; 2003
- Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Pegfilgrastim
Individual evidence
- ↑ Drugs.com: pegfilgrastim
